Lamivudine monotherapy-based cART is efficacious for HBV treatment in HIV/HBV co-infection when baseline HBV DNA<20,000IU/ml

BACKGROUND: Although combination antiretroviral therapy (cART) including tenofovir (TDF)+lamivudine (3TC) or emtricitabine (FTC) is recommended for treatment of HIV/HBV co-infected patients, TDF is unavailable in some resource-limited areas. Some data suggest that 3TC monotherapy-based cART may be e...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Acquir Immune Defic Syndr
मुख्य लेखकों: LI, Yijia, XIE, Jing, HAN, Yang, WANG, Huanling, ZHU, Ting, WANG, Nidan, LV, Wei, GUO, Fuping, QIU, Zhifeng, LI, Yanling, DU, Shanshan, SONG, Xiaojing, THIO, Chloe L, LI, Taisheng
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2016
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4977191/
https://ncbi.nlm.nih.gov/pubmed/26745828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000927
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन